Drug Trial Radar · NCT03486301
BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab
Last checked: Nov 19, 2026Latest source record: Nov 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
87
Actual
Start
Feb 15, 2018
Primary completion
Mar 31, 2024
Study completion Apr 30, 2024
Sponsor
- Lead sponsor
- Eikon TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Apr 3, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Conditions
- Tumor, Solid
Interventions
BDB001 (EIK1001)Drug
BDB001 (EIK1001) is an immunotherapy agent.
PembrolizumabDrug
Pembrolizumab is a potent humanized monoclonal antibody with high specificity of binding to the PD 1 receptor. Pembrolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability: incidence of adverse events and any dose limiting toxicityTime frame: Up to 30 months
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Florida Cancer Specialists
Sarasota, Florida
Atlantic Health
Morristown, New Jersey
Tennessee Oncology
Nashville, Tennessee
NEXT Oncology
San Antonio, Texas
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.